Naramig (Naratriptan Hydrochloride)

Naratriptan Hydrochloride, the active ingredient in Naramig, is a Triptan presented as an oral formulation for systemic use. It is indicated for the acute treatment of migraine attacks in adults and works by targeting specific serotonin receptors to alleviate headache symptoms.

GNH USA supplies Naramig as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Its global distribution network ensures timely delivery and compliance with local regulatory requirements.

Naratriptan is a Triptan medication used in the migraine pathway to provide rapid relief of headache symptoms.

- Migraine: aborts acute migraine attacks and reduces headache intensity. - Migraine with aura: alleviates pain and associated neurological symptoms during an attack. - Migraine-associated nausea: helps lessen nausea when taken early in the episode.

Commonly reported adverse reactions to naratriptan are generally mild and transient, while rare events may be serious and require medical attention.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: feeling unusually tired or weak. - Nausea: mild stomach upset or urge to vomit. - Dry mouth: reduced salivation causing throat discomfort. - Paresthesia: tingling or numbness in extremities. - Neck stiffness: mild muscular tension in the neck region.

Serious or Rare Side Effects: - Chest pain: discomfort that may indicate cardiac involvement. - Hypertension: sudden increase in blood pressure. - Serotonin syndrome: agitation, hyperthermia, and muscle rigidity when combined with serotonergic agents. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Coronary vasospasm: constriction of heart arteries causing ischemia. - Arrhythmia: irregular heart rhythm requiring urgent care.

Before prescribing naratriptan, clinicians should evaluate patient history and consider specific safety measures.

- Assess cardiovascular risk: review history of coronary artery disease, angina, or stroke before use. - Avoid concomitant ergot drugs: combined vasoconstriction may lead to severe vascular events. - Monitor serotonergic therapy: use caution with SSRIs, SNRIs, or MAO inhibitors to prevent serotonin syndrome. - Caution in uncontrolled hypertension: elevated blood pressure can be exacerbated by the drug. - Store at ambient temperature: keep tablets in the original container, protect from moisture and heat.

Naratriptan can interact with several medication classes; understanding the level of interaction helps guide safe co‑administration.

Major Interactions (Avoid): - Ergot derivatives: combined vasoconstriction may cause serious vascular complications. - Monoamine oxidase inhibitors (MAOIs): increased risk of serotonin syndrome when used together. - SSRIs and SNRIs: potential for serotonin syndrome, especially at high doses.

Moderate Interactions (Monitor Closely): - Other triptans: additive vasoconstrictive effect may increase cardiovascular risk. - Antihypertensive agents: naratriptan may enhance blood pressure‑lowering effects. - CYP1A2 inhibitors (e.g., fluvoxamine): may raise naratriptan plasma concentrations.